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Abstract
Background: Sarcoids are the mostcommon skin tumors in horses, characterized by rare regression, invasiveness and
high recurrence following surgical intervention and Delta Papillomaviruses are widely recognized as the causative agents
of the disease. In order to gain new insights into equine sarcoid development, we have evaluated, in 25 equine sarcoids,
by immunohistochemistry and western blotting analysis, the expression levels of VEGF, Ki67 and bcl-2. Moreover, we have
measured microvessel density and specific vessel parameters.
Results: All sarcoid samples showed a strong and finely granular cytoplasmatic staining for VEGF in the majority (90%)
of keratinocytes, sarcoid fibroblasts and endothelial cells. Numerous small blood vessels, immunostained with Von
Willebrand factor, often appeared irregular in shape and without a distinct lumen, with mean values of microvessel
area and perimeter lower than normal. Moreover, in all sarcoid samples, Ki67 immunoreactivity was moderately positive
in 5–10% of dermal sarcoid fibroblasts, while Bcl2 immunoreactivity was detected in 52% of the sarcoid samples, with a
weak staining in 20–50% of dermal sarcoid fibroblasts. Biochemical analysis was consistent with immunohistochemical
results.
Conclusions: This study has provided evidence that in equine sarcoid: VEGF was strongly expressed; the increased
number of vessels was not associated with their complete maturation, probably leading to a hypoxic condition, which
could increase VEGF synthesis; the levels of sarcoid fibroblasts proliferation were very low. Concluding, VEGF may have
a role in equine sarcoid development, not only through the increase of angiogenesis, but also through the control of
sarcoid fibroblast activity.
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Background
Sarcoids are the most common skin tumors in horses [1–3],
with prevalence rates ranging from 12.9 to 67% of all equine
tumors [4, 5]. They appear as benign fibroblastic skin tu-
mors, and are characterized by rare regression, invasiveness
and high recurrence following surgery [6–8]. Delta Papillo-
maviruses (Bovine Papillomavirus 1, Bovine Papillomavirus
2 and Bovine Papillomavirus 13) [9–11] are involved in the
pathogenesis of this tumor, mainly through the biological ac-
tivity of the E5 oncogene. It has also been reported that
BPV alters DNA methylation status and oxidative stress pa-
rameters [12, 13].
Moreover, equine sarcoid may be considered one of the
main long-term complications in the wound healing
process of the horse [5, 14], consequent to abnormal fibro-
blast proliferation and changes in dynamics of the extracel-
lular matrix (ECM) and its main components [15]. Altered
turnover of the ECM deposition and degradation, as result
of an altered expression of matrix metalloproteinases
(MMPs) and tissue inhibitor of metalloproteinases (TIMPs),
were reported as basic mechanism for these changes [15].
ECM remodeling is strictly correlated to angiogenesis [16],
as MMPs production is stimulated by many of the same
factors (VEGF; tumor necrosis factor alpha; basic fibroblast
growth factor) implicated in endothelial migration and for-
mation of new capillaries (angiogenesis) [17]. VEGF, also
known as vascular permeability factor (VPF), is a member
of the platelet-derived growth factor (PDGF) family of
growth factors, having a potent angiogenic activity and an
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important role in the modulation of ECM homeostasis and
remodeling [18, 19]. It is involved in numerous physio-
logical and pathological processes, such as embryonic
development [20], bone formation [21] wound healing
[22] and cancer [23–27], in which it is up-regulated by
oncogene expression, growth factors and hypoxia [28–30].
Moreover, it has been reported that Human Papillomavirus
type 16 E6 and E7 oncoproteins may contribute to tumor
angiogenesis by direct activation of the VEGF gene promoter
in human lung and cervical carcinoma [31–33].
Although the general role of VEGF in angiogenic pro-
cesses has been intensively studied [23–27], its specific
function in sarcoid development has not been investi-
gated, so far. In this regard, the aim of this study was to
evaluate in a subset of equine sarcoids, the levels of VEGF
expression in association with angiogenesis (evaluation of
microvessel density and specific vessel parameters), and
with Ki67 and bcl-2 expression.
Results
Histological features
Haematoxylin and eosin staining of examined sarcoids
(n = 25) showed the typical histological changes in their
epidermal (when present) and dermal component, as re-
ported by Martano et al. (2016) [15], such as: hyperkera-
tosis and epidermal hyperplasia often accompanied by
rete pegs; dermal fibroblasts usually oriented perpen-
dicular to the basal epidermal layer in a ‘picket fence’
pattern; abundant ECM; numerous small vessels irregu-
lar in shape.
Immunohistochemical and biochemical results
The expression patterns of VEGF, Ki67 and bcl-2 in 25
equine sarcoids and 5 normal skin samples are summa-
rized in Table 1.
In all normal skin samples, weak granular cytoplasmatic
VEGF immunopositivity was detected predominantly in
the basal layer of normal epidermis (Fig. 1a), while normal
fibroblasts were negative. Ki67 immunostaining was mod-
erate and restricted to the basal layer of epidermis and
hair follicle (Fig. 1b), while bcl-2 immunostaing was very
weak and in 2/5 samples was negative (Fig. 1c). Moreover,
in normal skin samples, blood vessels, immunostained
with vWF, appeared regular in shape and size, with a dis-
tinct lumen (Fig. 1d).
In all sarcoid samples the majority (90%) of keratinocytes,
neoplastic fibroblasts and endothelial cells showed a strong
and finely granular cytoplasmatic staining for VEGF (Fig. 2a;
secondary-only negative control Fig. 2b) and Ki67 immuno-
reactivity was strong in the majority (90%) of epidermal
and hair follicle basal cells and endothelial cells, while only
5–10% of neoplastic dermal fibroblasts were moderately
positive (Fig. 2c; secondary-only negative control Fig. 2d). In
18 out of 25 sarcoid samples (72%) bcl-2 immunoreactivity
was moderate in basal and parabasal layer of epidermis and
in 20–50% of fibroblasts located immediately under the epi-
dermis (Fig. 2e; secondary-only negative control Fig. 2f)),
while the percentage of bcl-2 positive dermal fibroblasts was
very low (10%) (Fig. 2g; secondary-only negative control
Table 1 Immunoreactivity scoring of VEGF, Ki67 and Bcl2 in 25
equine sarcoid samples and 5 equine normal skins
Samples Location VEGF Ki67 bcl-2
Staining
Intensity
Staining
Intensity
Staining
Intensity
S1 neck ++ + +
S2 limb ++ + +/−
S3 Pectoral
region
++ + +
S4 limb ++ + +/−
S5 head ++ + +/−
S6 abdomen ++ + +/−
S7 head ++ ++ –
S8 Pectoral
region
++ + +/−
S9 limb ++ + +/−
S10 (para)-Genital ++ + +/−
S11 Limb ++ + +
S12 abdomen ++ + n.a.
S13 Pectoral
region
++ ++ +/−
S14 head ++ + +
S15 limb ++ ++ –
S16 (para)-Genital ++ + +
S17 Limb ++ + +/−
S18 abdomen ++ + +
S19 Pectoral
region
++ + –
S20 neck ++ + +
S21 limb ++ + +
S22 (para)-Genital ++ ++ n.a.
S23 Limb ++ + +/−
S24 abdomen ++ ++ –
S25 Pectoral
region
++ +/− +/−
N1 head +/− + +/−
N2 abdomen +/− +/− –
N3 neck +/− + –
N4 limb +/− +/− +/−
N5 Pectoral
region
+/− + +/−
N Normal skin sample, S sarcoid sample, n.a. not assessable; − negative
staining; +/− weak immunolabelling; + moderate immunolabelling; ++
extensive and strong immunolabelling
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fig. h) and the intensity of staining was weak. Moreover,
in all sarcoid samples, numerous small blood vessels
often appeared irregular in shape (Fig. 2i; negative con-
trol Fig.l).
Microvessel density was lower in normal skin samples
(39.5 ± 2.1) than in sarcoid samples (84.8 ± 65.06), with not
statistically significant p value (p > 0.05), while vascular pa-
rameters mean values (area and perimeter) were higher in
normal skins (418.02 ± 84.14; 78.01 ± 7.07) than in sarcoid
samples (223.08 ± 55.92; 62.03 ± 6.08), with statistically sig-
nificant p value (p < 0,05) (Table 2).
Western blotting analysis was performed to check the
specificity of the antibodies used throughout the study (Fig.
3a-h). A band of the expected molecular size for VEGF (25
Kda), vWF (250 Kda), bcl-2 (26 Kda) and Ki67 (110 Kda)
was identified in the tested samples as well as in Hela or
Saos-2 cell lines used as positive control (Fig. 3a, c, e, f).
The densitometric analysis of the bands normalized for
β-actin revealed variable levels of VEGF protein among the
samples, with higher expression in two sarcoid samples
(Fig. 3b). Moreover, Von Willebrand factor protein was
over-expressed in each sarcoid sample compared to each of
normal skin lysates, in which the specific band was almost
undetectable (Fig. 3d). The biochemical expression of bcl-2
and Ki67 was variable among the samples and no different
trends between normal skin and tumor samples could be
pointed out as confirmed by densitometric analysis and
normalization for β-actin levels (Fig. 3f, h).
Discussion
VEGF is a potent angiogenic factor, produced by a variety
of cell types, including keratinocytes, endothelial cells,
macrophages, mast cells, fibroblasts [29, 34, 35] and is in-
volved in several types of tumors [23–27], where it has
been shown to influence both tumor neovascularization
and dissemination [36, 37]. Vascular endothelial growth
factor can occur in at least six different isoforms, contain-
ing 121, 145, 165, 183, 189 and 206 amino acids. VEGF
121 is a freely diffusible isoform [38] and it has been
proved to have a stronger angiogenic and tumorigenic ac-
tivity when compared to the bigger isoforms [39–41].
In the present study, for the first time, we have demon-
strated, by immunohistochemistry, the overexpression of
VEGF (isoform 121) in equine sarcoid compared to normal
skin, which was in part confirmed by biochemical analysis.
It appeared as a strong and finely granular cytoplasmic
staining pattern in the majority (> 90%) of keratinocytes,
endothelial cells and sarcoid fibroblasts, suggesting a pos-
sible role in equine sarcoid development. Interestingly, in
sarcoid samples we have also observed the presence of nu-
merous small vessels, immunostained with vWF, which ap-
peared often irregular in shape These findings were in
agreement with other studies, which reported that tumor
vasculature, formed under the influence of VEGF, is often
structurally and functionally abnormal [42], probably as the
results of the insufficient production or activation of other
angiogenic factors, necessary for the formation of mature
Fig. 1 Equine normal skin. Streptavidin-biotin-peroxidase stain. a weak granular cytoplasmatic VEGF immunostaining was detected in the basal
layer of epidermis and hair follicle while normal fibroblasts were negative 20×; b Ki67 immunostaining was moderate and restricted to the basal
layer of epidermis 40×; c bcl-2 immunostaining was very weak and restricted to the basal layer of epidermis 40×; d blood vessels,
immunolabeled with vWF, appeared regular in shape, with a distinct lumen 20×
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and functioning new vessels [25, 26]. These data seem to
strongly support the hypothesis that in sarcoid, a subopti-
mal blood flow could lead to a deficient oxygen gradient
within the tissue that exacerbates angiogenesis [43]. It is
well known that tissue mild hypoxia, an almost universal
condition within wound healing, from which sarcoid could
origin, is an effective inducer of VEGF synthesis [44].
Therefore, in sarcoid, a vicious circle may occur in which
hypoxia upregulates VEGF synthesis, leading to an insuffi-
cient vascularization, which in turn probably exacerbates
hypoxia. Despite numerous studies characterizing its angio-
genic property, data on the role of VEGF in ECM homeo-
stasis and remodeling are still scanty.
For this reason, we speculate that, in equine sarcoid,
VEGF could be implicated not only in angiogenesis but also
in ECM homeostasis and remodeling, through a deregula-
tion of fibroblasts proliferation and apoptosis in a possible
hypoxic condition. This mechanism was also reported dur-
ing endochondral bone formation, in which VEGF couples
hypertrophic cartilage remodeling, ossification and angio-
genesis [21]. In this regard, a very low fibroblast growth rate
has been reported in equine sarcoid, along with a low fre-
quency of p53 mutations [45]. These last were generally as-
sociated with abnormalities in apoptotic pathways rather
than abnormal cell cycle control mechanism [46].
In our sarcoids samples, the percentage of Ki67 positive
fibroblasts ranged from 5 to 10% and, in agreement with
previous studies [46–48], these results confirm that the rate
of fibroblast proliferation in equine sarcoid was very low.
Moreover, these observations correspond to the clinical evi-
dence that equine sarcoids are slow growing tumors and
can remain quiescent for years [47]. IHC and biochemical
data did not prove an overall differential expression of Ki67
and bcl-2 in sarcoids compared to normal skin; however,
the more frequent localization of BPV-positive cells, right
near the dermo-epidermal junction [49, 50], could explain
the higher expression of Ki67 and bcl-2 observed in epithe-
lial portion and in dermo-epidermal junction.
Conclusion
Concluding, in this study we hypothesized that VEGF
might have a role in sarcoid development, by altering
ECM homeostasis, through a selection of a quiescent
population of fibroblast, leading to an impaired degrad-
ation and excessive accumulation of ECM [14]. This also
seems to be also supported by our previous study, which
documented that the excessive and progressive deposition
of connective tissue (collagen) in sarcoid is not only the
result of elevated synthesis by fibroblasts, but it is also
caused by a deficiency in matrix degradation due to an alt-
erated expression of MMPs and TIMPs [15].
Currently, despite the numerous sarcoid treatment
choices available, not all sarcoids are responsive. Hence, the
importance of a better knowledge of equine sarcoid devel-
opment. Further studies in the near future are needed to in-
vestigate the association between equine sarcoid and tissue
Fig. 2 Equine sarcoid. Streptavidin-biotin-peroxidase stain. a
Keratinocytes and fibroblasts showed a strong and finely granular
cytoplasmatic staining for VEGF (arrow). 20×; b Secondary-only
negative control for VEGF. 20×; c Ki67 immunoreactivity was strong in
the epidermal and hair follicle basal cells (little arrow), while only few
dermal fibroblasts (big arrow) were moderately positive. 20×; d
Secondary-only negative control for Ki67. 20×; e Fibroblasts located
immediately under the epidermis were moderately positive for bcl2
(arrow). 40×; f Secondary-only negative control for bcl-2. 40×; g bcl-2
immunoreactivity was weak in few dermal fibroblasts (arrow). 40×; h
Secondary-only negative control for bcl-2 40×; i Numerous small blood
vessels, immunolabeled with vWF, often appered irregular in shape
and without a distinct lumen (arrow). 20×; l Secondary-only negative
control for bcl-2. 20×
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hypoxia, which could have a crucial role for the develop-
ment of new therapeutic strategies.
Methods
Tumor samples
A total of 25 (S1-S25) equine sarcoids (each from a
different horse), clinically identified based on their
gross morphology according to Pascoe and Knotten-
belt [51], were obtained from affected horses, which
underwent surgery routinely, adhering to a high
standard (best practice) of veterinary care, after in-
formed written consent of the owners, and according
to Directives 2010/63/EU (art. 1 c. 4) and 2010/63/
EU. Tumors were localized on the neck (2), limbs (8),
pectoral region (5), head (3), abdomen (4), (para)-ge-
nital (3) (Table 1). Sarcoid tissues used in this study
were known to be BPV positive [48].
As controls, tissues from 5 normal skin BPV posi-
tive samples (N1-N5), were taken during necropsy
from five healthy horses. We did not seek committee
approval as all samples analyzed were not collected as
part of experimental clinical veterinary practices but
as routine diagnosis and treatment, according to Dir-
ective 2010/63/EU (art. 1 c. 4) on protection of ani-
mals used for scientific purposes. All samples were
10% formalin fixed, paraffin-embedded for routine
histological processing and stained with haematoxylin
and eosin for light microscopy study.
Additional five sarcoids (S26-S30) and 2 normal skin sam-
ples (N6-N7) were collected as above and immediately fro-
zen at − 80 °C in order to allow Western blotting analysis.
Immunohistochemistry
Paraffin sections of equine sarcoids (S1-S25) and normal
skin (N1-N5) from healthy horses were dewaxed in xylene,
dehydrated in graded alcohols and washed in 0.01 M
phosphate-buffered saline (PBS), pH 7.2–7.4. Endogenous
peroxidase was blocked with hydrogen peroxide 0.3% in ab-
solute methanol for 30 min. The immunohistochemical pro-
cedure (streptavidin biotin-peroxidase method) for the
detection of VEGF, bcl-2, Ki67 and vWF was the same as
that used by the authors in a previous study [15]. The
immunolabelling procedure included negative control sec-
tions incubated with PBS instead of the primary antibodies
(Fig. 2b, d, f, h, l). Primary antibodies, dilutions and antigen
retrieval techniques used in this study are listed in Table 3.
Primary antibodies were diluted in phosphate-buffered
saline (PBS) and applied overnight at 4 °C. After 2 washes in
PBS, MACH 1 mouse probe (Biocare Medical, LLC, Con-
cord, CA, USA) was applied for 20 min at room
temperature. After, MACH-1 Universal HPR-Polymer
(Biocare Medical) was applied for 30 min at room
temperature. To reveal immunolabelling, diaminobenzidine-
tetrahydrochloride was used as a chromogen, and haema-
toxylin as counterstain.
Scoring of immunoreactivity
The intensity of immunolabelling in each specimen, for
each antibody, was scored by two independent ob-
servers (MM and KP) under blinded conditions, as per-
formed in a previous study [52]. Briefly, for each
sample the immunoreactivity was scored from negative
to strong, as follows: n.a., not assessable; − negative
staining; +/− weak immunolabelling; + moderate
immunolabelling; ++ extensive and strong immunola-
belling. Moreover, the number of positively-labelled
cells was established by counting 1.000 cells in 10 fields
(See figure on previous page.)
Fig. 3 Western blotting analysis of VEGF, vWF, bcl-2 and Ki67 protein expression in equine sarcoids (S) and normal skin samples (N). a VEGF was
expressed in all the analysed samples, with higher protein levels in S29 and S30. Hela whole cell lysate was run along with equine samples as
positive control. The membrane was re-probed for β-actin to allow normalization. b Densitometric values were measured and expressed as VEGF/
actin ratio. c vWF was detectable in sarcoids but not in normal skin samples. Saos-2 whole cell lysate was run along with equine samples as
positive control. The Saos-2 box is cut from the same membrane at a different exposure time and properly aligned according to the molecular
standard loaded onto the gel. The membrane was re-probed for β-actin to allow normalization. d Densitometric values were measured and
expressed as vWF/actin ratio. e bcl-2 was expressed at variable levels in the analysed samples. Hela whole cell lysate was run along with equine
samples as positive control. The membrane was re-probed for β-actin to allow normalization. f Densitometric values were measured and
expressed as bcl-2/actin ratio. g Variable expression of Ki67 protein in the analysed samples. Hela whole cell lysate was run along with equine
samples as positive control. The Hela box is cut from the same membrane at a different exposure time and properly aligned according to the
molecular standard loaded onto the gel. The membrane was re-probed for β-actin to allow normalization. h Densitometric values were measured
and expressed as Ki67/actin ratio
Table 2 Microvessel density and vascular parameters (areas and
perimeters), expressed as mean (X) and standard deviation (SD),
in equine sarcoids and normal skins
Normal skin
(X ± SD)
Equine sarcoids
(X ± SD)
p values
(< 0,05)
Microvessel density 39.5 ± 2.1 84.8 ± 65.06 0,3
Areas (mm2) 418.02 ± 84.14 223.08 ± 55.92 0,001
Perimeters (mm) 78.01 ± 7.07 62.03 ± 6.08 0,007
Martano et al. BMC Veterinary Research  (2018) 14:266 Page 6 of 9
at 400× magnification (40× objective 10× ocular) and
results were expressed as percentage.
Microvessel density and vascular parameter measurements
Microvessel density (number of vessels per mm2) and vas-
cular parameter measurements (vessel area and perimeter)
were performed on vWF immunostained sections, using a
free image analysis software (Image J). For each tumor 10
fields, randomly selected, were captured at 400× magnifica-
tion (40× objective 10× ocular) with a microscope (E-400;
Nikon Eclipse, Tokyo, Japan) coupled to a videocamera
(TKC1380E; JVC, Tokyo, Japan), stored in the digital mem-
ory, and shown on the monitor. The fields were examined
and manual outlining of immunolabelled microvessels was
performed; microvessel density, areas, perimeters were then
calculated based on image analysis, and results were
expressed as mean (X) and standard deviation values (±SD)
(Table 2). Statistical assessment was performed using a Stu-
dent t-test by analysis of variance (ANOVA) and p-value<
0.05 with 95% confidence interval (CI) was considered sta-
tistically significant.
Protein extraction and SDS PAGE/western blotting
Tissue samples N6-N7 and T26-T30 were homogenized in
ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Triton X100, 1 mM EDTA, deoxycholate 0.25%)
added with phosphatase and protease inhibitor cocktails
(Sigma-Aldrich, Milan, Italy) by using TissueLyser machin-
ery (Qiagen, Milan, Italy) according to manufacturer’s
protocol. Tissue homogenates were incubated on a rocking
wheel for 30′ at 4 °C. Protein extracts were clarified by
high-speed centrifugation at 4 °C for 30’and total proteins
were quantified by Bradford assay (Bio-Rad, Bio-Rad La-
boratories, Segrate (MI), Italy). Equal amounts of lysates
were resuspended in Laemmli sample buffer (Bio-Rad),
boiled and analyzed by denaturing polyacrylamide gel elec-
trophoresis (SDS PAGE). Proteins were blotted from gel
onto nitrocellulose membranes using TransBlot Turbo ap-
paratus (Bio-Rad, Bio-Rad Laboratories, Segrate (MI), Italy).
The membranes were blocked with 5% non-fat dry milk in
Tris buffered saline (10 mM Tris-HCl, pH 7.4, 165 mM
NaCl) with 0.1% tween (TTBS), for 1 h (h) at room
temperature (RT) and incubated over night at 4 °C with the
primary antibodies at the indicated dilutions: anti- Bcl2
(1:1000), anti-VEGF (1:200), anti-Ki67 (1:1000), anti-vWF
(1:1000). After four washing steps of 10 minutes, appropriate
peroxidase-conjugated secondary antibodies were applied
for 1 h at RT at 1:2000 dilution. Following further four
washings in TTBS, bound antibodies were visualized by en-
hanced chemiluminescence (Cyanagen, Bologna, Italy). The
blots were stripped and reprobed against mouse anti-β-actin
antibody (CP01, Calbiochem, San Diego, CA, USA) (1:500)
to allow normalization. Protein levels were quantitatively
estimated by densitometric analysis using ChemiDoc gel
scanner (Bio-Rad) equipped with a densitometric worksta-
tion (Image Lab software, (Bio-Rad Laboratories, Segrate
(MI), Italy). Proteins concentrations were normalized to
the β-actin levels.
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